Advanced Search:
Equity Index

CYAD.BR - CELYAD ONCOLOGY

€0.30  0 (0%)

Updated: 08:05 May 8, 2024 EST

Next Session's AI Forecast

-68.62%

Avg. Accuracy (AI)

€0.15

Next Week's AI Forecast

100%

Trend's Accuracy (AI)

€-0.57

CELYAD ONCOLOGY's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

CELYAD ONCOLOGY - HISTORICAL DATA 6M

  • Last price

    €0.30

  • Daily change

    €0

  • Previous Close

    €0.3035

  • Last Updated

    08:05 May 8, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
2.19 0.04 -0.3 -0.46 -0.17

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
2.93 3.42 2.87 3.14 3.82

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
100% 58.49% 34.83% 17.92%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
0.31 -3.12% 0.32 -3.03% 0.33 -17.5% 0.4

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
1 40.12 N/A N/A

CELYAD ONCOLOGY Technical Analysis News

CELYAD ONCOLOGY

Axis Business Park
Rue André Dumont 9
Mont-Saint-Guibert 1435
Belgium
32 1 039 41 00
https://www.celyad.com

Sectors: Healthcare
Industry: Biotechnology
F. Time Employees: 17
Description

Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; Multi-specific CAR T-cell platform that focuses on the NKG2D receptor; NKG2D-based CAR T-cell therapies; and B7-H6 targeting CAT T-cell therapies. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery / PerkinElmer for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Corporate Governance

Celyad Oncology SA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

CELYAD ONCOLOGY'S HOLDERS RANK

List of holders with stock participation in CELYAD ONCOLOGY.

Holder Rank Holder Shares Date Reported % Out Value